Steroid-induced Diabetes: is It Just Unmasking of Type 2 Diabetes?

Overview

Journal ISRN Endocrinol

Specialty Endocrinology

Date 2012 Jul 26

PMID 22830041

Citations 17

Authors

Lisa R Simmons

Lynda Molyneaux

Dennis K Yue

Elizabeth L Chua

Affiliations

Soon will be listed here.

Abstract

Aims. We compared the demographic profile and clinical characteristics of individuals with new onset steroid-induced diabetes (NOSID) to Type 2 diabetes (T2DM) patients with and without steroid treatment. Methods. The demographic profile and clinical characteristics of 60 individuals who developed NOSID were examined and matched to 60 type 2 diabetes patients receiving steroid therapy (T2DM+S) and 360 diabetic patients not on steroids (T2DM) for age, duration of diabetes, HbA1c, gender, and ethnicity. Results. Patients who developed NOSID had less family history of diabetes (P ≤ 0.05) and were less overweight (P ≤ 0.02). NOSID was more commonly treated with insulin. Despite a matching duration of diabetes and glycaemic control, significantly less retinopathy was found in the group of patients with NOSID (P < 0.03). Conclusions. It appears that steroid treatment primarily precipitated diabetes in a group of individuals otherwise less affected by risk factors of diabetes at that point in time, rather than just opportunistically unmasking preexisting diabetes. Furthermore, the absence of retinopathy suggests that patients with NOSID had not been exposed to long periods of hyperglycaemia. However, the impact of the underlying conditions necessitating steroid treatment and concomitant medications such as immunosuppressants on diabetes development remain to be defined.

Citing Articles

Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?.

Pofi R, Caratti G, Ray D, Tomlinson J Endocr Rev. 2023; 44(6):975-1011.

PMID: 37253115 PMC: 10638606. DOI: 10.1210/endrev/bnad016.

Practical Guide to Glucocorticoid Induced Hyperglycaemia and Diabetes.

Barker H, Morrison D, Llano A, Sainsbury C, Jones G Diabetes Ther. 2023; 14(5):937-945.

PMID: 36961675 PMC: 10037401. DOI: 10.1007/s13300-023-01393-6.

Pathophysiology, Diagnostic Criteria, and Approaches to Type 2 Diabetes Remission.

Khamis A Cureus. 2023; 15(1):e33908.

PMID: 36819346 PMC: 9936340. DOI: 10.7759/cureus.33908.

Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions.

Li J, Cummins C Nat Rev Endocrinol. 2022; 18(9):540-557.

PMID: 35585199 PMC: 9116713. DOI: 10.1038/s41574-022-00683-6.

Endocrine Follow-up During Post-Acute COVID-19: Practical Recommendations Based on Available Clinical Evidence.

Pal R, Joshi A, Bhadada S, Banerjee M, Vaikkakara S, Mukhopadhyay S Endocr Pract. 2022; 28(4):425-432.

PMID: 35158058 PMC: 8832848. DOI: 10.1016/j.eprac.2022.02.003.

References

McGill M, Molyneaux L, Yue D, Turtle J . A single visit diabetes complication assessment service: a complement to diabetes management at the primary care level. Diabet Med. 1993; 10(4):366-70. DOI: 10.1111/j.1464-5491.1993.tb00082.x. View

. Standards of medical care in diabetes--2009. Diabetes Care. 2009; 32 Suppl 1:S13-61. PMC: 2613589. DOI: 10.2337/dc09-S013. View

Cameron A, Dunstan D, Owen N, Zimmet P, Barr E, Tonkin A . Health and mortality consequences of abdominal obesity: evidence from the AusDiab study. Med J Aust. 2009; 191(4):202-8. DOI: 10.5694/j.1326-5377.2009.tb02753.x. View

Clore J, Thurby-Hay L . Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009; 15(5):469-74. DOI: 10.4158/EP08331.RAR. View

Clement S, Braithwaite S, Magee M, Ahmann A, Smith E, Schafer R . Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004; 27(2):553-91. DOI: 10.2337/diacare.27.2.553. View

Lambillotte C, Gilon P, Henquin J . Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest. 1997; 99(3):414-23. PMC: 507814. DOI: 10.1172/JCI119175. View

Hollingdal M, Juhl C, Dall R, Sturis J, Veldhuis J, Schmitz O . Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia. 2002; 45(1):49-55. DOI: 10.1007/s125-002-8244-y. View

Genuth S . The UKPDS and its global impact. Diabet Med. 2008; 25 Suppl 2:57-62. DOI: 10.1111/j.1464-5491.2008.02504.x. View

Marchetti P . New-onset diabetes after liver transplantation: from pathogenesis to management. Liver Transpl. 2005; 11(6):612-20. DOI: 10.1002/lt.20439. View

10.

Giannarelli R, Coppelli A, Boggi U, Rizzo G, Barsotti M, Palaeologo G . New-onset diabetes after kidney transplantation. Diabet Med. 2005; 22(8):1125-6. DOI: 10.1111/j.1464-5491.2005.01621.x. View

11.

Wei J, Li H, Wang Y, Chuang L, Lin M, Lin C . Detailed family history of diabetes identified children at risk of type 2 diabetes: a population-based case-control study. Pediatr Diabetes. 2009; 11(4):258-64. DOI: 10.1111/j.1399-5448.2009.00564.x. View

12.

Keenan H, Costacou T, Sun J, Doria A, Cavellerano J, Coney J . Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care. 2007; 30(8):1995-7. DOI: 10.2337/dc06-2222. View

13.

Valderhaug T, Hjelmesaeth J, Rollag H, Leivestad T, Roislien J, Jenssen T . Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. Transplantation. 2007; 84(9):1125-30. DOI: 10.1097/01.tp.0000287191.45032.38. View

14.

Kern W, Stange E, Fehm H, Klein H . [Glucocorticoid-induced diabetes mellitus in gastrointestinal diseases]. Z Gastroenterol. 1999; Suppl 1:36-42. View

15.

Lachin J, Genuth S, Cleary P, Davis M, Nathan D . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342(6):381-9. PMC: 2630213. DOI: 10.1056/NEJM200002103420603. View

16.

Mohamed Q, Gillies M, Wong T . Management of diabetic retinopathy: a systematic review. JAMA. 2007; 298(8):902-16. DOI: 10.1001/jama.298.8.902. View

17.

Arner P, Gunnarsson R, Blomdahl S, Groth C . Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care. 1983; 6(1):23-5. DOI: 10.2337/diacare.6.1.23. View

18.

Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L . WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabet Med. 2004; 21(4):383-7. DOI: 10.1111/j.1464-5491.2004.01115.x. View

19.

BOOKMAN J, DRACHMAN S, SCHAEFER L, ADLERSBERG D . Steroid diabetes in man; the development of diabetes during treatment with cortisone and corticotropin. Diabetes. 1953; 2(2):100-11. DOI: 10.2337/diab.2.2.100. View

20.

Fong D, Aiello L, Ferris 3rd F, Klein R . Diabetic retinopathy. Diabetes Care. 2004; 27(10):2540-53. DOI: 10.2337/diacare.27.10.2540. View